Hertfordshire and West Essex ICB
Prescribing, Policies and Pathways
Prescribing, Policies and Pathways
The last day of operation for Hertfordshire and West Essex ICB was 31 March 2026. The information on this website has not been updated since 31 March 2026. The legacy policies, prescribing recommendations and pathways can be accessed on this website. Find out more
or
| Medicine / Guideline | Indication | RAG rating | Document type | Place |
|---|---|---|---|---|
| Acenocoumarol | Treatment and prevention of thromboembolic diseases. | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Alirocumab | Primary hypercholesterolaemia and mixed dyslipidaemia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Aliskiren | Hypertension | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Alteplase | Acute ischaemic stroke | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ambrisentan | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Amiodarone | Arrythmia | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Amiodarone Review Pathway | Arrythmia | Amber protocol | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Anagrelide | Reduction of elevated platelet counts | Red | n/a | Hertfordshire and West Essex ICB |
| Andexanet alfa | Reversal of anticoagulation for gastrointestinal tract bleed | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Andexanet alfa | Reversing anticoagulation for intracranial haemorrhage | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Arrhythmia | n/a | Clinical pathways | South and West Hertfordshire | |
| Aspirin dipyridamole clopidogrel | Occlusive vascular events prevention | n/a | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Atrial Fibrillation (AF) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Bempedoic acid | Primary hypercholesterolaemia or mixed dyslipidaemia | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Bosentan | Digital ulcers and pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Cangrelor | Reduction of atherothrombotic events in PCI | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Chest Pain | n/a | Clinical pathways | South and West Hertfordshire | |
| Cilostazol | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ciprofibrate | Hypercholesterolaemia | Double Red | n/a | Hertfordshire and West Essex ICB |
| Colesevelam | Bile acid sequestrants for prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Colestyramine | Bile acid sequestrants for prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dalteparin | Anticoagulation | Red | n/a | Hertfordshire and West Essex ICB |
| Dapagliflozin | Chronic Heart Failure | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Dapagliflozin Switch Guidance | n/a | Prescribing guideline | Hertfordshire and West Essex ICB | |
| Diagnosing Asymptomatic Heart Murmur | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| DOAC (best value DOAC - 1st line generic apixaban & rivaroxaban) | Treatment for non-valvular atrial fibrillation | Green | n/a | Hertfordshire and West Essex ICB |
| DOACs | DOAC patient counselling checklist | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| DOACs | Anticoagulation - Atrial fibrillation (AF) guidance | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Doxazosin (prolonged release) | Hypertension, benign prostatic hyperplasia (BPH) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Doxazosin 8mg to 4mg tablets-switch-letter | Hypertension | n/a | Patient information | Hertfordshire and West Essex ICB |
| Dronedarone - Adults | Arrythmia | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Empagliflozin | Chronic Heart Failure | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Enoxaparin | Anticoagulation | Red | n/a | Hertfordshire and West Essex ICB |
| Evolocumab | Primary hypercholesterolaemia and mixed dyslipidaemia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Exercise Protocol for the Management of CHD (Exercise for Cardiac Conditions) | n/a | Clinical pathways | East and North Hertfordshire | |
| Fludrocortisone | Orthostatic Hypotension | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Gemfibrozil | Hypercholesterolaemia | Double Red | n/a | Hertfordshire and West Essex ICB |
| Heart Failure | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Heart Valve Disease | n/a | Clinical pathways | South and West Hertfordshire | |
| Hypertension guidelines in adults | Hypertension | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Hypertension in Adults - Diagnosis and Initial Management | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Icosapent ethyl | Hypertriglyceridemia | Red | Decision document | Hertfordshire and West Essex ICB |
| Inclisiran | Primary hypercholesterolaemia and mixed dyslipidaemia | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Inclisiran | Primary hypercholesterolaemia and mixed dyslipidaemia | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Inclisiran (letter to providers and GP practices 01/2025) | Primary hypercholesterolaemia and mixed dyslipidaemia | n/a | n/a | Hertfordshire and West Essex ICB |
| Inositol nicotinate | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ivabradine | stable angina and chronic heart failure | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Left Ventricular Systolic Dysfunction (LVSD) Management | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Lipid management | patient decision aid statin therapy | n/a | Patient information | Hertfordshire and West Essex ICB |
| Lipid management pathway | Statin intolerance | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Lipid management pathway | Primary & secondary prevention | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Lomitapide | Homozygous familial hypercholesterolaemia (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Low molecular weight heparin (LMWH) | Anticoagulation | Red | Decision document | Hertfordshire and West Essex ICB |
| Macitentan | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Metolazone | Oedema | n/a | Patient information | Hertfordshire and West Essex ICB |
| Metolazone | Oedema | Red | Decision document | Hertfordshire and West Essex ICB |
| Mexiletine | Life threatening ventricular arrhythmias (unlicensed - acute provider only) | Red | n/a | Hertfordshire and West Essex ICB |
| Midodrine | Orthostatic Hypotension | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Naftidrofuryl Oxalate | Intermittent claudication in people with peripheral arterial disease | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Nicotinic acid | Prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Omega 3 fatty acid | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Omega 3 fatty acid | Hypertriglyceridaemia - severe | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Omega-3 Fatty Acids Patient Information Leaflet | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | n/a | Patient information | Hertfordshire and West Essex ICB |
| Palpitations | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Pentoxifylline | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Perindopril arginine | Heart failure, hypertension and prophylaxis of CV events | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Perindopril Arginine Patient information leaflet | Heart failure, hypertension and prophylaxis of CV events | n/a | Patient information | Hertfordshire and West Essex ICB |
| Phenindione | Anticoagulant therapy in the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation, for prophylaxis after insertion of prosthetic heart valves and for prophylaxis and treatment of venous thrombosis and pulmonary embolism. | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Prasugrel | Percutaneous coronary intervention (PCI) for treating acute coronary syndromes (ACS) | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ranolazine | Angina stable | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Rivaroxaban | Prevention of atherothrombotic events in patients after an acute coronary syndrome | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Rivaroxaban | Preventing atherothrombotic events in people with coronary or peripheral artery disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Sacubitril valsartan | Heart failure | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Sildenafil (20mg tablets) | Pulmonary arterial hypertension (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
| Statin patient decision aid - NICE | Hypercholesterolaemia | n/a | Patient information | Hertfordshire and West Essex ICB |
| Syncope Care Pathway | n/a | n/a | South and West Hertfordshire | |
| Tenecteplase | Acute ischaemic stroke | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Test Syncope Care | n/a | n/a | South and West Hertfordshire | |
| Ticagrelor | Preventing atherothrombotic events after myocardial infarction | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ticagrelor | Treatment of acute coronary syndromes | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Varicose Veins Management | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Vericiguat | Heart failure - chronic with reduced ejection fraction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Vernakalant | Atrial fibrillation | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |